InstalabLoading...
InstalabLoading...
If you keep getting sinus infections, bronchitis, or pneumonia and nobody can explain why, a normal total antibody level on routine bloodwork might be hiding the answer. IgG3 (immunoglobulin G subclass 3) is the most common individual antibody subtype to be selectively low in adults who have a normal overall IgG level. That means your standard immune panel can look perfectly fine while a specific, functionally important piece of your defense system is quietly missing.
IgG3 is also the antibody subtype your body reaches for first during many viral infections. It activates the complement system (a cascade of proteins that punch holes in invaders) and triggers immune cells to engulf pathogens more effectively than the other three IgG subtypes. When it is low, your immune response loses a key weapon. When it is high, it can signal an active infection, an autoimmune process, or, in some newer research, may help distinguish multiple sclerosis from other neurological conditions.
Your immune system makes four subtypes of IgG antibodies, numbered 1 through 4. Each has a slightly different structure and job. IgG3 stands out because of its long, flexible hinge region (the middle section of the antibody that bends to latch onto targets), which lets it grab onto invaders more easily and trigger stronger immune reactions. It binds tightly to receptors on immune cells that carry out killing and engulfing, and it activates complement more powerfully than the other subtypes.
The trade-off for all that firepower is a shorter lifespan. IgG3 circulates in your blood for roughly 7 days before being cleared, compared to about 21 days for IgG1. This means your body needs to keep producing it steadily, and any disruption to B cell function (the immune cells responsible for making antibodies) can cause IgG3 to drop faster than other subtypes.
The most established clinical use for IgG3 testing is in adults and children who have recurrent upper respiratory infections, chronic sinusitis, or bronchitis despite normal total IgG levels. In a study of 432 adults evaluated for antibody deficiency, IgG subclass deficiency was a common finding, with IgG3 deficiency frequently appearing alongside normal total IgG. Patients with IgG subclass deficiency had distinct patterns of infection and autoimmune conditions compared to those with broader immune deficits like common variable immunodeficiency (CVID), a more severe form of antibody failure.
A separate study of 64 adults with IgG subclass deficiency found that these patients had measurably lower activity of regulatory T cells (immune cells that keep the immune system in balance) and altered patterns of immune signaling molecules. Immunoglobulin replacement therapy partially restored some of these immune functions, suggesting the deficiency has real downstream consequences beyond just a low number on a lab report.
In adults with chronic obstructive pulmonary disease (COPD), IgG subclass deficiencies as a group were linked to more frequent respiratory exacerbations and hospitalizations, though studies found that IgG1 and IgG2 levels were the strongest independent predictors of these outcomes rather than IgG3 specifically. Separately, IgG3 deficiency has been identified as the most common single subclass deficiency in adults with normal total IgG levels who were referred to immunology for recurrent infections.
IgG3 tends to appear early during viral infections, often as one of the first high-quality antibodies your immune system produces. In studies of chikungunya virus, patients who developed IgG3 antibodies early in the illness cleared the virus faster and had less long-term joint pain. In acute hepatitis C, early IgG1 and IgG3 responses targeting the viral envelope protein were associated with clearing the virus rather than developing chronic infection.
During the COVID-19 pandemic, researchers found that IgG3 was among the first antibody subtypes produced against SARS-CoV-2. In a study of 348 patients, IgG3 concentrations were significantly associated with disease severity, with higher levels appearing in sicker patients. A separate analysis of 536 patients confirmed that an imbalanced IgG subclass composition, including prominent IgG3, correlated with more severe disease. This is not a contradiction with IgG3 being protective: a strong IgG3 response reflects the immune system working hard against a serious threat, and the severity likely drives the antibody level rather than the other way around.
In HIV vaccine research, IgG3 antibodies targeting specific parts of the virus envelope correlated with reduced infection risk and lower viral levels in those who did become infected. This has made IgG3 a target of interest for vaccine designers trying to elicit the most protective immune responses.
The same potent immune-activating abilities that make IgG3 good at fighting infections can cause tissue damage when misdirected. In heart failure, IgG3 autoantibodies targeting receptors on heart muscle cells (called beta-1 adrenergic receptors) have been identified in a study of 121 patients with chronic systolic heart failure and a larger cohort of 353 patients with recent-onset cardiomyopathy. The IgG3 subclass of these autoantibodies was functionally significant, meaning the specific subtype mattered for how the antibody affected heart function.
In organ transplantation, donor-specific IgG3 antibodies are associated with worse outcomes. A study of 105 liver transplant recipients found that those with IgG3 donor-specific antibodies had a higher risk of chronic rejection and graft loss. In kidney transplantation, a high proportion of IgG3 among donor-specific antibodies was independently linked to more severe antibody-mediated rejection, likely because IgG3's strong complement activation drives more intense tissue injury.
A newer line of research has connected IgG3 to autoimmune disease through the gut. A study in both mice and humans found that a gut bacterium (Enterococcus gallinarum) that crosses the intestinal barrier into the bloodstream can trigger the production of IgG3 autoantibodies targeting RNA, a pattern associated with systemic lupus erythematosus and autoimmune hepatitis. Because part of this evidence comes from animal models, more human research is needed to confirm the full pathway.
In a study of 191 patients, higher serum IgG3 levels distinguished multiple sclerosis (MS) from other neurological disorders. This elevation was found in the blood, not in the cerebrospinal fluid, suggesting it reflects a systemic immune shift rather than just local brain inflammation. If confirmed in larger studies, serum IgG3 could become part of a blood-based screening approach for MS, though this application is still in early stages.
IgG3 is typically the least abundant IgG subclass in blood, making up roughly 4 to 8% of total IgG. Levels vary meaningfully by sex, race, and the specific lab method used. In a study of 12,751 adults, Black and Asian patients had higher mean IgG3 levels than White patients, and women generally had higher levels than men. Using a single universal reference range can misclassify people, so your result is best interpreted in the context of your lab's specific reference interval and your demographic profile.
| Category | Approximate Range (g/L) | What It Suggests |
|---|---|---|
| Normal adult range | 0.15 to 0.80 | Typical IgG3 production; range varies by lab, sex, and ethnicity |
| Low (potential deficiency) | Below 0.15 to 0.20 | May indicate selective IgG3 deficiency if total IgG is normal; correlate with clinical history |
| Elevated | Above lab upper limit | Could reflect active infection, autoimmune activity, or chronic immune stimulation |
These ranges are approximate and drawn from published literature. Your specific lab will report its own reference interval based on its assay method (usually a technique called nephelometry, which measures how much light scatters when antibodies in your sample bind to test particles). Compare your results within the same lab over time for the most meaningful trend.
IgG3 measurement can be affected by factors that have nothing to do with your actual immune function. Understanding these helps you avoid acting on a number that does not reflect reality.
A single IgG3 reading is a snapshot, and like any snapshot, it can be misleading. Immunoglobulins show relatively low within-person biological variation, which is good news for serial monitoring: it means a genuine change in your level is more likely to be real and less likely to be random noise. But it also means you need consistent testing conditions to catch true shifts.
If your first result is low, retest in 4 to 8 weeks using the same lab and method. A persistently low IgG3 on two or more readings, especially alongside recurrent infections, is much more meaningful than a single low value. If you are receiving immunoglobulin replacement therapy, periodic retesting (every 3 to 6 months) helps confirm that your trough levels are adequate and your infection frequency is decreasing.
For anyone using IgG3 as a window into immune health more broadly, an annual check alongside your other immune markers gives you a personal baseline. If you see a sustained downward trend over multiple readings, that is worth investigating even if each individual result still falls within the reference range.
If your IgG3 comes back low, the first step is to repeat the test to confirm the finding. If it is confirmed, check the other IgG subclasses (IgG1, IgG2, IgG4), total IgG, IgA (immunoglobulin A), and IgM (immunoglobulin M) to see whether the deficiency is isolated or part of a broader pattern. An immunologist can then assess your ability to make specific antibodies to vaccines (typically using the pneumococcal polysaccharide vaccine as a challenge test), which determines whether the low IgG3 is functionally significant.
If your IgG3 is elevated, the clinical context matters most. In the setting of an active infection, a high IgG3 is expected and usually resolves on its own. Persistently elevated IgG3 without an obvious infection should prompt evaluation for autoimmune conditions, and the specific pattern of other markers (ANA, complement levels, other IgG subclasses) will guide the workup. If MS is a concern based on neurological symptoms, the combination of elevated serum IgG3 with other MS-specific findings can support further investigation.
For transplant recipients, IgG3 subclass analysis of donor-specific antibodies adds risk information beyond what total donor-specific antibody levels show. If you are post-transplant and your team is monitoring for rejection, ask whether IgG subclass testing of your donor-specific antibodies is being performed.
Evidence-backed interventions that affect your IgG3 level
IgG3 is best interpreted alongside these tests.